论文部分内容阅读
目的观察贝伐单抗联合伊立替康治疗晚期结直肠癌的临床疗效。方法选取结直肠癌患者60例为研究对象,随机分为对照组和观察组,每组30例。对照组采用伊立替康治疗,观察组采用贝伐单抗联合伊立替康治疗。观察比较2组患者治疗效果、远期回访及不良反应发生率。结果观察组有效率高于对照组,不良反应发生率低于对照组,观察组远期回访时间高于对照组,差异有统计学意义(P<0.05)。结论贝伐单抗联合伊立替康治疗结直肠癌疗效确切,提高生存时间,降低不良反应发生率,疗效显著,值得临床推广应用。
Objective To observe the clinical efficacy of bevacizumab combined with irinotecan in the treatment of advanced colorectal cancer. Methods Sixty patients with colorectal cancer were selected as research object and randomly divided into control group and observation group, 30 cases in each group. The control group was treated with irinotecan, while the observation group was treated with bevacizumab combined with irinotecan. The therapeutic effect, long-term follow-up and incidence of adverse reactions in the two groups were observed and compared. Results The effective rate of the observation group was higher than that of the control group, and the incidence of adverse reactions was lower than that of the control group. The long-term follow-up time of the observation group was higher than that of the control group (P <0.05). Conclusion Bevacizumab combined with irinotecan treatment of colorectal cancer exact effect, improve survival time and reduce the incidence of adverse reactions, a significant effect, worthy of clinical application.